Background: End-of-life (EOL) cancer care in Japanese acute care hospitals has not been well described. Methods: We aimed to assess the aggressiveness of EOL care and examine common treatments administered to cancer patients using a health administrative database. Subjects are adult cancer patients who died at acute care hospitals between April 2011 and March 2014. Data from the Japanese Diagnosis Procedure Combination database were analysed to measure the aggressiveness of care (chemotherapy, intensive care unit [ICU] admission and cardiopulmonary resuscitation [CPR]) and describe procedures and prescriptions administered in the last 14 and 30 days of life, disaggregated by hospital case volume: high, intermediate and low volumes. Results: Of 248,978 cancer decedents, 170,024 died in high-, 70,231 in intermediate-and 8,723 in low-volume hospitals. Aggressive treatment in the last 14 days of life included chemotherapy (9.4%, 7.3%, and 5.4%, respectively), ICU admission (3.0%, 2.0%, and 2.4%) and CPR (5.8%, 6.4%, and 8.3%). Opioids were administered to 66.0%, 59.0% and 49.4% patients, while Palliative Care Team intervention was performed for 8.5%, 2.2% and 2.0% of patients, respectively in the last 30 days. In high-volume hospitals, radiotherapy and certified outpatient chemotherapy fees were more frequent. Catecholamines and hyperalimentation were more frequently administered in lowvolume hospitals. Conclusion: This is the first study to assess EOL care among Japanese acute care hospitals. More frequent use of chemotherapy at high-volume hospitals may reflect a well-established cancer treatment system. The approach for low-volume hospitals might improve the EOL care for all cancer patients in Japan.
Introduction
There has been an increase in observational research using a health administrative database to understand the nature, quality and costs of end-of-life (EOL) care for cancer patients (1) (2) (3) (4) . The quality of EOL care, especially with respect to aggressive treatment, such as intensive use of chemotherapy and resorting to life-sustaining treatment, hospitalization, intensive care unit (ICU) admission and emergency room visits and less use of hospice services are some of the key themes investigated in recent studies (2) (3) (4) (5) (6) . Indicators related to these services were identified by Earle et al., and their association with the quality of life has been revealed in some respects (5, 6) . Monitoring of these procedures and providing feedback to medical providers would help them examine their own practice and facilitate quality improvement (7) .
In Japan, the Diagnosis Procedure Combination (DPC) dataset is one part of the healthcare administrative data (8) (9) (10) . The DPC payment system was developed to evaluate the costs and quality of medical services mainly in acute care hospitals. The DPC dataset includes information about patients and detailed information on procedures/ interventions during their admission. The former includes age, sex, diagnosis, length of stay, comorbidity at admission and complications recorded in accordance with the International Classification of Diseases, 10th Revision (ICD-10) codes (8, 9) . The latter information is based on public insurance claims data for procedures, drugs and hospital charges. Approximately 20% of all Japanese hospitals are DPC hospitals; DPC hospitals accounted for half of all general hospital beds in 2012. Approximately 90% of all cancer-related deaths in Japan in 2012 occurred in hospitals, including 9% at inpatient palliative care units (11) . Therefore, an estimated 40% of cancer-related deaths ostensibly occur in DPC hospital, which makes it a valuable source of data to assess inpatient EOL care.
To the authors' knowledge, only two studies have reported on EOL care in Japan (12, 13) . Morishima et al. reported about the aggressiveness of EOL care in 3 294 cancer decedents, using the claim data that was submitted to the National Health Insurance and Long Life Medical Care System in Kyoto prefecture (12) . Although, it measured the quality of EOL care for the first time in Japan with the administrative database, the indicators were limited and the majority of the study subjects were 65 years of age or older only in a certain region. Sato et al. reviewed medical treatment administered to 2 802 cancer patients in the last two weeks of their life at 37 palliative care units across Japan (13) . However, the setting of the study was limited to palliative care units. Therefore, further information is needed to understand the EOL cancer care in Japan.
In this study, we aimed to assess not only the aggressiveness of EOL care but also the routine treatment administered to cancer patients in their EOL with use of DPC data from acute care hospitals in Japan.
Methods

Database, study population
In Japan, all specialty hospitals (university hospital, national cancer hospitals and the National Cerebral and Cardiovascular Center Hospital) are required to use the DPC payment system, which is a case-mix classification system that is linked with a lump-sum payment system for inpatient care reimbursement (10) . Other general hospitals use the DPC system at their own discretion. It was developed to evaluate the cost and quality of medical services mainly in acute care hospitals. General hospitals, which play a key role for cancer treatment in each region, tend to have the acute care function. In 2011, the DPC system was introduced at all 388 designated cancer hospitals. Therefore, analysis based on the DPC database is likely to be representative of EOL cancer care in Japanese acute care hospitals.
The DPC data was collected directly from the hospitals, which agreed to participate in the study. This study was approved by the Ethics Committee at the Tokyo Medical and Dental University (registration number 788). The number of study participating hospital in 2011 was 1057, which covered 52% of all acute inpatient care beds in Japan (10) .
We selected cancer decedents in the period between April 2011 and March 2014 from the discharge summary of DPC data. Inclusion criteria were as follows: (1) age ≥20 years; (2) the clinical outcome of discharge was death and (3) the registered ICD-10 code of the main disease and/or the disease that accounted for most of the treatment costs was C00-97 (malignant neoplasm; Table 1 ). The ICD-10 code of suspected disease, if any, was ignored. Exclusion criteria were as follows; (1) deaths occurring in hospitals where DPC data for both inpatients and out-patients were not available; and (2) deaths that occurred in the palliative care units at DPC hospitals. We had previously explored the methodology for DPC data analysis for monitoring of EOL care and certified its feasibility at a single centre (14) . It revealed that DPC data analysis could capture the problems in the real world, although the data of inpatient palliative care unit could not be obtained.
As described above, although DPC data was needed to include discharge summary and inpatient procedure information, many hospitals have made DPC data from outpatient claim data at their discretion. Therefore, we selected them to obtain both inpatient and outpatient information of treatments.
Measures
To describe the treatment of cancer patients in EOL settings at acute care hospitals, we chose the quality indicators of aggressiveness (chemotherapy, ICU admission and cardiopulmonary resuscitation [CPR] ); the common treatments are shown in Table 2 . We also described the common drugs administered to cancer patients; cytotoxic agents, molecular target agents, granulocyte-colony stimulating factor (G-CSF), antiemetics, opioids, NSAIDs, acetaminophen, corticosteroid, antibiotics, catecholamine, blood products, human albumin preparations, midazolam, sedative drugs, intravenous hyper alimentation and artificial hydration (100 mL or more). Chemotherapy was defined as a prescription of cytotoxic agents and/or molecular target agents. Opioids included morphine, oxycodone and fentanyl. Corticosteroids included dexamethasone and betamethasone. Antiemetics included the drugs on the Japanese Antiemetic Guideline, excluding corticosteroids: 5-HT3 receptor antagonists, NK-1 antagonists, domperidone and metoclopramide. Sedative drugs included flunitrazepam, phenobarbital, propofol and hydroxyzine. The mode of administration and dosage of the drugs were not distinguished for the purpose of this analysis.
The names of procedures were classified originally based on the Japanese health insurance system codes: intervention of the Palliative Care Team (PCT), mechanical ventilation, cardiac massage, tracheal intubation, radiation therapy, rehabilitation, extrahour emergent visit, oxygen inhalation, electrocardiogram (ECG) monitoring, certified outpatient chemotherapy, central venous catheterization, general anaesthesia, nerve block and haemodialysis. Intervention of the PCT was defined as the palliative care additional fee, which could be claimed at certified hospitals. The dataset distinguishes tracheal intubation for resuscitation from that used for general anaesthesia and other examinations, so the latter were excluded. Fee for cancer-specific rehabilitation care provided by trained personnel has been incorporated in the Japanese claims system since 2010. Additional fees for certified outpatient chemotherapy was chargeable in the certified hospitals in order to facilitate adequate human resources and infrastructure for chemotherapy.
Patient characteristics included sex, age, primary cancer site, Charlson Comorbidity Index, level of consciousness at the last admission, length of hospital stay, outpatient visit history and information of death at designated cancer care hospital. Primary cancer sites were classified according to the Cancer Registry and Statistics in Japan (15) . Records coded as malignant neoplasms of independent multiple sites (C97) were included as 'others'. Charlson Comorbidity Index was calculated with a maximum of 12 disease codes mentioned in the discharge summary (16) .
Analyses
The case volume reflected the hospitals' and physicians' experience with EOL care (12) . Hospitals were divided into tertiles; hospitals that reported >100 cancer decedents in a year were categorized as high-volume, those that reported 25-99 and <24 decedents in a year were categorized as intermediate-volume and low-volume hospitals, respectively. Relative frequencies and 95% confidence intervals (CI) were calculated for all variables in the last 14 or 30 days before death. Between-group differences with respect to patient characteristics were assessed with Wilcoxon rank-sum test, Chi-squared test, or Fisher's exact test, as appropriate. A p-value of <0.05 was considered statistically significant. All statistical analyses were performed with SAS version 9.4 for Windows (SAS Institute, Cary, NC).
Results
A total of 248,978 cancer decedents were identified between April 2011 and March 2014. The number of hospitals was 1178 (61.3%-68.4% of all Japanese DPC hospitals). Of these, 254 (21.6%) hospitals were designated cancer care hospitals. Out of the total 248,978 cancer decedents, 170,024 died in high-volume hospitals, 70 231 died in intermediate, and 8 723 died in low-volume hospitals. Forty percent of all patients died at designated hospitals, including 53% at high-volume hospitals.
Patient characteristics are summarized in Table 1 . Mean (±stand-ard deviation) age of patients in high-volume hospitals was 71 (±12) years, while those in intermediate-and low-volume hospitals were 74 (±12) years and 76 (±12) years, respectively. Men accounted for 63%, 62% and 59% of patients, respectively. Distribution of the primary cancer site was comparable in all three categories of patients. Overall, lung (C33-34, 19%), gastric (C16; 11%), haematological malignancy (C81-85, 88, 90-96; 10%) and colorectal (C18-20; 9%) cancer were the most common types of cancer. The number of outpatient visits in low-volume hospitals was significantly lower (28%, p < 0.0001) than that in high-and intermediatevolume hospitals (82% and 68%, respectively). The median length of the last hospitalization was 23 days, though 34% of all decedents stayed for <14 days, and 27% stayed for 15-30 days. The number of patients who had clear consciousness in the low-volume hospitals (76%, p < 0.0001) was significantly less than that in intermediateand high-volume hospitals (85% and 82%, respectively).
With respect to aggressive care in the last 14 days of life, 9.4% of all patients in high-volume hospitals were administered chemotherapy compared to 7.3% of patients in intermediate-volume hospitals and 5.4% in low-volume hospitals. Among hospitals classified as low-volume hospitals, 48% did not administer chemotherapy to patients in the last 30 days of their life. ICU admission rates (3.5%, 2.0% and 2.4%, respectively) were comparable between the three categories of hospitals. CPR in the last 14 days was more frequently performed in low-volume hospitals (8.3%, p < 0.0001) as compared to that in intermediate-and high-volume hospitals (5.8% and 6.4%, respectively). Table 3 shows the drug usage in EOL cancer care in Japanese acute care hospitals. At high-volume hospitals, a cytotoxic agent was used in the last 30 days of life in 16.7% (95% CI 16.6%-16.9%) patients and in 7.6% (7.4%-7.7%) patients in the last 14 days of life. Opioid prescription in low-volume hospitals (49.4%) was less frequent compared with that in high-(66%) and intermediate-volume hospitals (59.0%). At the low-volume hospitals, catecholamine (21.1%, 95% CI 20.3%-22.0%) and intravenous hyperalimentation (20.2%, 95% CI 19.3%-21.0%) were more frequently provided in the last 14 days of life. Table 4 shows the treatments conducted at EOL. In the highvolume hospitals, PCT (8.5%, 95% CI 8.3%-8.6%), radiation therapy (12.7%, 95% CI 12.6%-12.9%), cancer-specific rehabilitation (2.2%, 95% CI 2.1%-2.2%) and certified outpatient chemotherapy 
Discussion
In this study, we examined the details of treatment administered to cancer patients in their terminal stages of life at acute care hospitals in Japan disaggregated by case volume for the first time. This is one of the largest studies on a population-based retrospective cohort sourced from a health administrative database. The findings could be of benefit to patients, providers and policy makers in Japan. The major findings were as follows: 1) chemotherapy was administered more frequently at high-volume hospitals in the last 14 days of life (high-volume hospitals 9.4%, medium volume hospitals 7.3% and low-volume hospitals 5.4%); 2) at the low-volume hospitals, opioids were less frequently prescribed, while aggressive interventions, such as CPR, catecholamine and hyperalimentation, were more frequently administered; 3) at high-volume hospitals, cancer treatment and care services were found to be well-established, as reflected in the high rates of interventions, such as PCT, cancerspecific rehabilitation and certified outpatient chemotherapy. Morishima et al. reported no significant association between chemotherapy use and case volume in Japan (12) . Our findings, which are based on a large study population, provide new insights on the treatment and procedures performed for terminally ill cancer patients. In this analysis, chemotherapy was conducted mostly in the highvolume hospitals in Japanese acute care hospitals. However, it was less aggressive as compared to that reported in a previous review (1%-19% and 10%-38% in the last 14 and 30 days of life, respectively) (1). However, this may be attributable to different study settings.
In this study, up to half of all low-volume hospitals did not administer chemotherapy, which may reflect the poor experience of cancer patients. Among patients treated at low-volume hospitals, patients older than 80 years accounted for 43% of all patients; only 28.1% had a history of outpatient visits, and only 75.6% had clear consciousness at admission. These findings suggest that low-volume hospitals likely encounter more cancer patients with relative contraindications for chemotherapy at diagnosis owing to the poor general condition, older age and those who do not need intensive cancer care. However, the higher rate of CPR, catecholamine and hyperalimentation may indicate less experience in palliative care or poor quality of EOL care. There should be opportunities for improvement of EOL care in these hospitals, such as training of personnel in palliative care, promotion of referral to centres who are better equipped to administer EOL care and to raise awareness on the importance of advance directives among citizens to minimize unnecessary intensive treatment in EOL care.
More frequent PCT intervention, radiation therapy, certified outpatient chemotherapy fee and cancer-specific rehabilitation reflects the greater institutional experience and support for EOL care. In Japan, the Cancer Control Act was established in 2006 and executed in 2007. It promoted delivery of specialized and standardized cancer treatment at the core hospitals in every region. The high-volume hospitals included in this study played a key role in their respective catchment areas.
Some limitations of our study should be noted. The subjects included some patients who died of causes other than cancer because the patients were identified solely from the DPC database. It was not allowed to link data from other patient databases such as cancer registries and death certificate data. Further, patients who survived with some aggressive care were excluded from this study. It is common limitation in the administrative data study that we could not identify that the treatments were appropriated for the cases or followed by guidelines. Some treatment-related data was not available, especially if the treatment was provided outside the hospital prior to the hospitalization. As the DPC data were anonymized in each hospital at the time of collection, we could not link the information about a patient between the participating and/or non-participating hospitals. Because of it, the comorbidity index measured in this study might be underestimated. Our findings may not apply to hospice care, home-based care and long-term inpatients. Further analysis using an administrative database of health insurance claims could be useful to reveal these differences.
The strengths of this study include the large geographically representative dataset and inclusion of all cancer types and the presence of insured people. The findings of the study may be extrapolated to the acute care setting because almost 60% of all Japanese DPC hospitals participated in the study.
In conclusion, this is the first population retrospective cohort study based on data from the health administrative database, DPC database, which provides vital insights into the EOL treatment for terminally ill cancer patients at acute care centres in Japan. This information will provide a benchmark for each hospital to improve EOL care. Further study is needed to reflect the different disease course based on the primary cancer site and to measure QI of EOL care continually.
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